Patent SG-11201408292Y-A (SG)
Title: Dry powder for inhalation formulation comprising salmeterol xinafoate, fluticasone propionate and tiotropium bromide, and method for preparing same
Inventor: KIM KYEONG SOO
IPC: A61K9/16
Filed: 2013-06-03
Abstract: (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 19 December 2013 (19.12.2013) WIPOIPCT (10) International Publication Number WO 2013/187626 A1 (51) International Patent Classification: A61K 9/14 (2006.01) A61K31/56 (2006.01) A61K9/16 (2006.01) A61K31/166 (2006.01) (21) International Application Number: (22) International Filing Date: (25) Filing Language: (26) Publication Language: PCT/KR2013/004880 3 June 2013 (03.06.2013) English English (30) Priority Data: 10-2012-0063665 14 June 2012 (14.06.2012) KR (71) Applicant: HANMI PHARM. CO., LTD. [KR/KR]; #893-5, Hajeo-ri, Paltan-myeon, Hwaseong-si, Gyeong- gi-do 445-910 (KR). (72) Inventors: KIM, Kyeong Soo; 113-1902, 85, Hwasan-ro, Jangan-gu, Suwon-si, Gyeonggi-do 440-710 (KR). LEE, Deokkyu; 1222-402, 50, Mokdongdong-ro, Yangcheon- gu, Seoul 158-772 (KR). KIM, Dong Ho; 809-ho, 12, Seongnam-daero 172beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do 463-853 (KR). KIM, Yong II; 147-2201, 57, Hwasan-ro, Paldal-gu, Suwon-si, Gyeonggi-do 442-872 (KR). PARK, Jae Hyun; 311-404, 460, Yeongtong-ro, Yeongtong-gu, Suwon-si, Gyeonggi-do 443-737 (KR). WOO, Jong Soo; 120-2303, 85, Hwasan-ro, Jangan-gu, Suwon-si, Gyeonggi-do 440-330 (KR). (74) Agent: FIRSTLAW P.C.; Trust Tower, 275-5, Yang- jae-Dong, Seocho-Ku, Seoul 137-739 (KR). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) (54) Title: DRY POWDER FOR INHALATION FORMULATION COMPRISING SALMETEROL XINAFOATE, FLUTIC­ ASONE PROPIONATE AND TIOTROPIUM BROMIDE, AND METHOD FOR PREPARING SAME Aerodynamic size distribution salmeterol of CJ i> 00 i-H en i-H o CJ o & O) m o & C0 M— o E 3 CO El Example 1 Example 1 (Handyhaler®) • 10 Urnim • 30 L/mim Z2 60 L/mim Ofl 90 L/mim Example 5 Comp. Ex. 2 Comp. Ex. 3 (57) Abstract: Provided is a dry powder for inhalation formulation comprising salmeterol xinafoate, fluticasone propionate and tio - tropium bromide, as pharmaceutically active ingredients, and a carrier, and an inhalation formulation comprising same. The invent - ive dry powder inhalation formulation having good content uniformity and showing small changes in the aerodynamic size distribu - tion in accordance with the flow rate changes can effectively deliver said pharmaceutically active ingredients to a target site upon ad - ministration, and thus can be useful in the prevention or treatment of respiratory diseases, particularly asthma and COPD.